Navigation Links
PuraMed BioScience Discusses Potential for Patent Portfolio Acquisition
Date:5/30/2013

SCHOFIELD, Wis., May 30, 2013 /PRNewswire/ -- PuraMed BioScience®, Inc., (OTCBB:PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced an online interview to discuss recent developments, and the potential acquisition of a health and beauty products patent portfolio.

Highlights of the almost seven-minute interview, include:

  • Revenue Potential for LipiGesic® M Could Exceed $50 Million
  • Expanding Retail Chain-Store Distribution
  • Expansion into International Markets
  • Potential Patent Portfolio Acquisition Worth Millions
  • Market Capitalization Currently under $1 Million

Revenue Potential
Russ Mitchell , the Chairman and CEO of PuraMed BioScience, commented that with nearly 60 million Americans suffering from migraines the revenue potential for LipiGesic M, their over-the-counter migraine pain relief product, could generate over $50 million in sales annually by capturing just 1 percent of the migraine market.

Mr. Mitchell also discussed expanding distribution for their over-the-counter migraine pain reliever product, LipiGesic M, which is currently available in approximately 15,000 Walgreen's and CVS/pharmacy stores in all 50 states in the United States. According to Mr.Mitchell, he expects LipiGesic M to expand distribution into additional chains and wholesalers including all major retailers known to carry health and beauty products.

Off air, Mr. Mitchell said, "This expanded distribution would include mass merchandisers such as Wal-Mart and Target; food-store chains such as SuperValu, Kroger, and Safeway; as well as regional drugstore chains, which would add approximately another 21,000 stores."

In addition to US distribution, PuraMed BioScience has received its initial order from Columbia and has plans to expand to other Latin American countries as well as other regions around the world.

Patent Portfolio Acquisition
In the interview, Mr. Mitchell discussed current negotiations to acquire a patent portfolio of products in the anti-inflammatory, anti-bacterial, and anti-viral categories. Upon completion of the acquisition, PuraMed BioScience intends to license some of these patents to larger key manufacturers or bring these products to market directly. Mr. Mitchell commented, "Each one of those categories is huge, and has the potential to bring in many millions of dollars of additional revenue as these products get placed into the market."

To access the online interview please visit http://www.wallstreetnewscast.com/profile/pmbs.html

About PuraMed BioScience, Inc.
PuraMed BioScience engages in the research, development, and marketing of non-prescription medicinal and healthcare products. In addition to LipiGesic M, www.lipiGesic.com, PuraMed BioScience plans to launch LipiGesic H for tension-type headaches and LipiGesic PM, which provides a remedy for insomnia and other sleep disorders. www.puramedbioscience.com

Forward-Looking Statements
This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties that may cause actual results and future achievements of PuraMed BioScience to be materially different from those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.

Contact:
Melissa Diaz ,
South Street Media, Inc
Phone: (917) 937-8968
Email: info@southstreetmedia.com


'/>"/>
SOURCE PuraMed BioScience, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
2. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
3. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
4. Neurocrine Biosciences Reports First Quarter 2012 Results
5. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
8. HUYA Bioscience International Engages In Partnership With Zhuhai Sanzao Science and Technology Industrial Park
9. Tethys Bioscience and Lose it! Announce a Strategic Partnership to Support Diabetes Prevention
10. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
11. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2018)... (PRWEB) , ... September 14, 2018 , ... ... “Rare Diseases." This campaign showcases the innovative work being done within rare diseases ... therapies for those living with rare diseases. , The print ...
(Date:9/13/2018)... ... September 13, 2018 , ... The ultimate fitness experience has hit Astoria. A ... new arrival is called Form50 Fitness . , The studio practices the Lagree ... - a hybrid Pilates reformer with pulleys, weights, grasps and glides. The method and ...
(Date:9/13/2018)... ... 13, 2018 , ... AccentCare, Inc., a nationwide leader in ... regional Texas Home Health operations the largest Texas-based post-acute care provider offering ... care services. , Texas Home Health operations serve all 254 counties in Texas, ...
Breaking Medicine Technology:
(Date:9/24/2018)... ... September 24, 2018 , ... A groundbreaking ceremony will be ... new affordable assisted living community for Indianapolis seniors who need some help to maintain ... Glasswater Lane, will serve seniors of all incomes. The new road is located at ...
(Date:9/24/2018)... ... September 24, 2018 , ... As a leader in ... respective patients, clients, and students improve their movement or mobility and strength and live ... to OS Instructor status. Mike is a Coach/Instructor at Tucson Strength located ...
(Date:9/24/2018)... N.C. (PRWEB) , ... September 24, 2018 , ... A ... human cord blood can ease fibrosis and inflammation in a painful type of skin ... malignant tumors, a frequent side effect of RDEB, from forming. , An estimated 25,000 ...
(Date:9/23/2018)... ... September 23, 2018 , ... ... that specializes in working with healthcare, small business and non-profit organizations, announced ... Delivery System Reform Incentive Payment (DSRIP) Technical Assistance (TA) Program and the ...
(Date:9/22/2018)... ... ... Located on the fourth floor in the East Pavilion at Tampa General ... 1. The 8,500 square-foot unit featuring 16 private rooms is the first of its ... like TGH that provides excellent, innovative care,” said Andrew Molosky, MBA, FACHE, CHPCA, president ...
Breaking Medicine News(10 mins):